Literature DB >> 17641374

High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases.

Klaus Strobel1, Reinhard Dummer, Daniela B Husarik, Marisol Pérez Lago, Thomas F Hany, Hans C Steinert.   

Abstract

PURPOSE: To prospectively determine the accuracy of positron emission tomography (PET)/computed tomography (CT) with added CT morphologic information for depiction of metastases in patients with high-risk melanoma and negative findings for metastases at PET, by using histologic findings or additional imaging and/or follow-up findings as reference standard.
MATERIALS AND METHODS: Institutional review board approval was obtained. Informed consent was obtained from patients. One hundred twenty-four consecutive high-risk melanoma patients (65 female, 59 male; mean age, 54.4 years; range, 15-82 years) were included. Fluorine 18 fluorodeoxyglucose (FDG) PET/CT was performed. First, PET/CT scans were evaluated for presence of metastases with increased FDG uptake; CT anatomic location was determined. Lesions were considered metastases if there was focal uptake higher than that of background tissue. Second, coregistered CT images of combined PET/CT scans were evaluated for presence of lesions without FDG uptake. Findings were compared with reference standard findings to determine the accuracy of each evaluation. McNemar test was used to assess statistical differences in accuracy.
RESULTS: In 53 of 124 patients, metastases were found. In 46 of 53 patients with metastases, lesions had increased FDG uptake. In seven patients with metastatic disease, metastases did not have increased FDG uptake (maximum standard uptake value [SUV], <1.5; n = 5) or had faint FDG uptake (maximum SUV, 2.5 and 2.9; n = 2)-findings that were inconclusive with PET alone. These lesions were interpreted as metastases only with coregistered CT images. Lesions missed with PET were located in the lungs, iliac lymph nodes, subcutis, and psoas muscle. Sensitivity, specificity, and accuracy, respectively, of PET/CT for depiction of metastases were 85%, 96%, and 91%, and those of PET/CT with dedicated CT interpretation were 98%, 94%, and 96% (P = .016).
CONCLUSION: Dedicated analysis of coregistered CT images significantly improves the accuracy of integrated PET/CT for depiction of metastases in patients with high-risk melanoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17641374     DOI: 10.1148/radiol.2442061099

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  31 in total

Review 1.  Positron emission tomography for benign and malignant disease.

Authors:  Anthony Visioni; Julian Kim
Journal:  Surg Clin North Am       Date:  2011-02       Impact factor: 2.741

Review 2.  Metabolic positron emission tomography imaging in cancer detection and therapy response.

Authors:  Aizhi Zhu; Daniel Lee; Hyunsuk Shim
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

3.  (18)F-FDG PET/CT imaging in a seldom case of primary malignant melanoma of duodenum.

Authors:  Sachin Jain; Punit Sharma; Sellam Karunanithi; Chandrasekhar Bal; Rakesh Kumar
Journal:  Indian J Nucl Med       Date:  2015 Jan-Mar

4.  [Whole-body staging of malignant melanoma: advantages, limitations and current importance of PET-CT, whole-body MRI and PET-MRI].

Authors:  C Pfannenberg; N Schwenzer
Journal:  Radiologe       Date:  2015-02       Impact factor: 0.635

5.  The value of 18F-FDG-PET/CT imaging for sinonasal malignant melanoma.

Authors:  S K Haerle; M B Soyka; D R Fischer; K Murer; K Strobel; G F Huber; D Holzmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-06-29       Impact factor: 2.503

Review 6.  Machine learning in quantitative PET: A review of attenuation correction and low-count image reconstruction methods.

Authors:  Tonghe Wang; Yang Lei; Yabo Fu; Walter J Curran; Tian Liu; Jonathon A Nye; Xiaofeng Yang
Journal:  Phys Med       Date:  2020-07-29       Impact factor: 2.685

7.  Imaging of gastrointestinal melanoma metastases: Correlation with surgery and histopathology of resected specimen.

Authors:  Ahmed E Othman; Thomas K Eigentler; Georg Bier; Christina Pfannenberg; Hans Bösmüller; Christian Thiel; Claus Garbe; Konstantin Nikolaou; Bernhard Klumpp
Journal:  Eur Radiol       Date:  2016-10-17       Impact factor: 5.315

8.  Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B.

Authors:  Klaus Strobel; Reinhard Dummer; Hans C Steinert; Katrin Baumann Conzett; Karin Schad; Marisol Pérez Lago; Jan D Soyka; P Veit-Haibach; Burkhardt Seifert; V Kalff
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-06       Impact factor: 9.236

9.  Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma.

Authors:  K Strobel; B Bode; R Dummer; P Veit-Haibach; D R Fischer; L Imhof; S Goldinger; Hans C Steinert; G K von Schulthess
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-04       Impact factor: 9.236

10.  Current concepts of metastasis in melanoma.

Authors:  Blazej Zbytek; J Andrew Carlson; Jacqueline Granese; Jeffrey Ross; Martin C Mihm; Andrzej Slominski
Journal:  Expert Rev Dermatol       Date:  2008-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.